Is Firmagon Safer or More Tolerable Than Lupron? | Mark Scholz, MD | PCRI

Описание к видео Is Firmagon Safer or More Tolerable Than Lupron? | Mark Scholz, MD | PCRI

Medical oncologist Mark Scholz, MD, answers questions from our YouTube comments on whether Firmagon is a safer and more tolerable alternative to Lupron.

0:03 Can you share your thoughts on whether Firmagon is safer or more tolerable than Lupron?

1:54 You said that you tend to start people on Firmagon and then switch to a more convenient option like Lupron, Trelstar, or Eligard. Is Orgovyx also a good option to switch to?

Don’t know your stage? Take the quiz: Visit http://www.prostatecancerstaging.org

To learn more about prostate cancer visit http://www.pcri.org

To receive the latest updates on prostate cancer and the PCRI, sign up for our online newsletter here: https://pcri.org/join

Who we are:

The Prostate Cancer Research Institute (PCRI) is a 501(c)(3) not-for-profit organization that is dedicated to helping you research your treatment options. We understand that you have many questions, and we can help you find the answers that are specific to your case. All of our resources are designed by a multidisciplinary team of advocates and expert physicians, for patients. We believe that by educating yourself about the disease, you will have more productive interactions with your medical professionals and receive better individualized care. Feel free to explore our website or call our free helpline at 1 (800) 641-7274 with any questions that you have. Our Federal Tax ID # is 95-4617875 and qualifies for maximum charitable gift deductions by individual donors.

The information on the Prostate Cancer Research Institute's YouTube channel is provided with the understanding that the Institute is not engaged in rendering medical advice or recommendation. The information provided in these videos should not replace consultations with qualified health care professionals to meet your individual medical needs.

#ProstateCancer #Prostate #MarkScholzMD

Комментарии

Информация по комментариям в разработке